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People with diabetes and peripheral artery disease (PAD) have a high risk of 
major adverse cardiovascular events (MACE). Prior research suggests that 
medical therapies aimed to control modifiable risk factors are poorly imple-
mented in patients with PAD.
AIM 
To examine the association between the control of modifiable risk factors, 
estimated by the novel PAD-medical score, and the incidence of MACE in people 
with PAD and diabetes.
METHODS 
Participants were recruited from out-patient clinics if they had a diagnosis of both 
PAD and diabetes. Control of reversible risk factors was assessed by a new 
composite measure, the PAD-medical score. This score takes into account the 
control of low-density lipoprotein cholesterol, blood pressure, blood glucose, 
smoking and prescription of an anti-platelet. Participants were followed to record 
incidence of myocardial infarction, stroke and cardiovascular death (MACE). The 
association of PAD-medical score with MACE was assessed using Cox propor-
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tional hazard analyses adjusting for age, sex and prior history of ischemic heart 
disease and stroke.
RESULTS 
Between 2002 and 2020, a total of 424 participants with carotid artery disease (n = 
63), aortic or peripheral aneurysm (n = 121) or lower limb ischemia (n = 240) were 
prospectively recruited, and followed for a median duration (inter-quartile range) 
of 2.0 (0.2–4.4) years. Only 33 (7.8%) participants had the optimal PAD-medical 
score of five, with 318 (75%) scoring at least three out of five. There were 89 
(21.0%) participants that had at least one MACE during the follow-up period. A 
one-unit higher PAD-medical score was associated with lower risk of MACE (HR 
= 0.79, 95%CI: 0.63-0.98) after adjusting for other risk factors.
CONCLUSION 
The PAD-medical score provides a simple way to assess the control of modifiable 
risk factors targeted by medical management aimed to reduce the incidence of 
MACE.
Key Words: Peripheral artery disease; Diabetes; Major cardiovascular events; Medical 
management; Prospective study; Clinical practice
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Core Tip: The control of modifiable risk factors for major adverse cardiovascular events 
(MACE) is frequently poorly achieved in patients with peripheral artery disease 
(PAD). The PAD-medical score is an easy way to assess the control of modifiable risk 
factors. In the current study only 33 (7.8%) of the included participants had optimal 
control of risk factors evidenced by a maximum PAD-medical score. Adjusted analyses 
found that a one-unit higher PAD-medical score was associated with a significantly 
lower risk of MACE (HR = 0.79, 95%CI: 0.63-0.98).
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Diseases of the aorta and its branches (peripheral artery disease; PAD) are a collection 
of chronic occlusive and aneurysmal diseases, such as carotid artery disease, 
abdominal aortic aneurysm and lower limb ischemia[1-4]. Depending on study entry 
criteria and testing, between 10% and 60% of people with PAD have been reported to 
have diabetes[5]. Poorly controlled diabetes, as estimated by high hemoglobin A1c 
(HbA1c) concentrations, has been associated with an increased risk of major adverse 
cardiovascular events (MACE; myocardial infarction, stroke or cardiovascular death) 
in people with PAD[6,7], with approximately 20% having events during short-term 
follow-up[8-13].
Randomised controlled trials have demonstrated that medical therapies that control 
key cardiovascular risk factors, such as reducing low density lipoprotein-cholesterol 
(LDL-c) concentrations[11,14], blood pressure[15] and blood glucose[16], and reducing 
the risk of thrombosis[17], are effective at substantially reducing the risk of MACE. In 
clinical practice, however these therapies are poorly implemented[5,8,18-20]. Prior 
studies have suggested that poor implementation of medical therapies are associated 
with a higher incidence of MACE, but are limited through largely focusing on 
assessing the control of individual risk factors, such as blood pressure or LDL-c alone
[8,18,19]. A holistic assessment of implementation of medical therapies amongst 
people with PAD and diabetes would consider control of all key modifiable risk 
factors.
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The first aim of this study was to examine the implementation of all the key medical 
therapies in accordance with current clinical guidelines in a group of people that had 
both PAD and diabetes. This included achieving optimal control of serum LDL-c, 
systolic blood pressure, HbA1c, smoking abstinence and prescription of an anti-
platelet medication[21-23]. This was measured through the introduction of a new 
algorithm, PAD-medical, designed to quantify the relative control of the key 
modifiable risk factors targeted by optimal medical management. Secondly, this study 
aimed to examine the association of implementation of these combined medical 
therapies, estimated by the relative control of modifiable risk factors using PAD-
medical score, with the incidence of MACE, adjusted for other risk factors.
MATERIALS AND METHODS
Study design and participants
This investigation was designed as part of an ongoing prospective cohort study that 
commenced in 2002, and aimed to identify risk factors associated with PAD outcomes
[24,25]. The current study included adult participants (≥ 18 years old) with a prior 
history of a diagnosis of both diabetes and PAD, presenting to the outpatient vascular 
services at The Townsville University Hospital, the Mater Hospital Townsville and 
The Royal Brisbane and Women’s Hospital in Queensland, Australia. People 
presenting with carotid artery disease, an abdominal or peripheral aneurysm or lower 
limb PAD diagnosed by a vascular specialist were eligible as long as they had a prior 
diagnosis of diabetes based on documented medical records from previous visits[26,
27]. Participants presenting without diagnoses of both diseases were excluded.
Lower limb PAD was defined to include symptoms of leg or foot pain or tissue loss 
and absence of lower limb pulses, ankle-brachial index ≤ 0.9 or imaging evidence of a 
lower limb artery stenosis of ≥ 50% or occlusion[24,25]. Abdominal aortic aneurysm 
(AAA) was diagnosed if the orthogonal maximum outer to outer infra-renal aortic wall 
diameter was ≥ 30 mm measured from ultrasound or computed tomographic 
angiography[24,25]. Peripheral aneurysms were defined to include common or 
internal iliac artery diameters ≥ 15 and ≥ 8mm respectively, or femoral or popliteal 
artery diameters of ≥ 15 mm and ≥ 9 mm respectively, as previously described[28]. A 
significant carotid artery stenosis was defined as ≥ 50% using Australian Society for 
Ultrasound in Medicine criteria[24,25]. Written informed consent was obtained from 
all participants upon entry into the study. The study was performed in accordance 
with the Helsinki declaration and ethical approval was granted from the James Cook 
University and Townsville Hospital Health Service human research ethics committees 
(HREC/13/QTHS/125 and HREC/14/QTHS/203).
Risk factors and assessment of medical management
The implementation of medical management was assessed using a composite measure, 
the PAD-medical score, which was developed for this study in order to assess the 
control of the key modifiable risk factors targeted to reduce the risk of MACE[5,8,18,
29-31]. This scoring tool was developed to address the lack of an existing tool which 
applies to all age groups, and includes the relevant medical risk factors for people with 
concomitant PAD and diabetes (e.g., HbA1c). The PAD-medical has a possible score of 
between 0 and 5, with zero indicating worst implementation of medical management 
and five indicating best implementation of medical manage-ment.
PAD-medical was calculated based on the control of key risk factors, smoking 
history and anti-platelet prescription measured at study entry. PAD-medical used risk 
factor targets for preventing MACE in patients with PAD indicated by current clinical 
guidelines[21-23], with each target achieved scoring one point. Values for some risk 
factors indicating partial control were scored either 0.25 or 0.5 points. The PAD-
medical score was thus calculated as follows: Serum LDL-C: ≥ 3.0 mmol/L = 0, 2.5-2.9 
mmol/L = 0.25; 1.8-2.4 mmol/L = 0.5; < 1.8 mmol/L = 1; Systolic blood pressure: > 160 
mmHg = 0; 140-160 mmHg = 0.5; < 140 mmHg = 1; HbA1c: > 9% = 0; 7%-9% = 0.5; < 
7% = 1; Smoking history: not smoked within the last month = 1; smoked within the last 
month = 0; Prescribed an anti-platelet medication: confirmed receiving = 1; not 
receiving = 0.
Definition and assessment of outcomes
At entry, participants underwent fasting blood tests, resting blood pressure was 
measured using an Omron Intellisense (HEM-907) monitor and smoking history and 
prescribed medications were recorded[8]. All prescribed medications including 
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antiplatelet drugs, statins and diabetes medications were recorded. Serum LDL-C, 
HbA1c and C-reactive protein were measured as previously described[27,32]. Ischemic 
heart disease (IHD) was defined as a history of myocardial infarction, angina or 
previous treatment for IHD[33].
Participants were offered follow up annually as part of standard care, and 
outpatient follow up was performed according to local clinical practice. Outcome data 
were recorded during clinical reviews on prospectively defined case report forms. 
Hospital charts and electronic records were also reviewed by a vascular specialist. 
Outcome data were also obtained from linked hospital admission records as pre-
viously described[24,25,34,35]. Linked data were obtained from the Queensland 
Hospital Admitted Patient Data Collection (QHAPDC) which is regularly audited to 
minimize inaccuracies[36]. The primary outcome was MACE, defined as the first 
occurrence of a major cardiovascular event including myocardial infarction, stroke or 
cardiovascular death.
Sample size
It was aimed to have adequate power to test the hypothesis that the PAD-medical 
score was associated with the risk of MACE. Previous studies suggest that approx-
imately 30% of people with PAD have a MACE during short term follow-up[8,9,34]. 
Monte-Carlo simulations suggest that a multivariable regression model is powered 
sufficiently when 10 outcome events per degree of freedom of the predictor variables 
are observed[37]. Assuming an incidence of MACE of 20% to 30%, and planning to 
adjust for PAD-medical score (a composite of five risk factors), age, sex, IHD and 
stroke in the regression models, it was estimated that a sample size of over 400 
participants would have adequate power to test the main hypothesis.
Statistical analysis
Data were analysed using the SPSS v25 (IBM, Armonk, NY, United States) software 
package. Continuous data that were not normally distributed, as confirmed using the 
Shapiro Wilk test, were presented as median and inter-quartile range (IQR). Between-
group comparisons were conducted using the Mann-Whitney U and Kruskal-Wallis 
tests. Categorical variables were compared using Pearson’s χ2 test. Cox proportional 
hazard analyses assessed the association of PAD-medical score (one unit increase) 
with MACE adjusted for age, sex, smoking, IHD and prior stroke. Results were 
presented as hazard ratios (HR) and 95% confidence intervals (CI). P values of < 0.05 
were accepted to be significant for all of these analyses.
RESULTS
Participants and implementation of medical management
Between February 2002 and August 2020, 424 participants with comorbid diabetes and 
PAD presenting with carotid artery disease (n = 63), aortic or peripheral aneurysm (n = 
121) or lower limb ischemia (n = 240) were recruited. Only 33 (7.8%) of the participants 
had the optimal PAD-medical score of 5, with 173 (40.8%) scoring ≥ 4, and 318 (75.0%) 
scoring ≥ 3. Sex, age and history of IHD varied significantly between participants with 
different PAD-medical scores (Table 1). As expected, participants with the higher 
PAD-medical scores had significantly lower HbA1c, LDL-c and systolic blood 
pressure, reduced frequency of current smoking, and more frequent prescription of 
anti-platelet and statin medications (Table 2).
Association of PAD-medical score with MACE
Participants were followed for a median of 2.0 (0.2-4.4) years. During this time, 89 
(21.0%) participants had at least one MACE. Overall, 43 participants had a myocardial 
infarction, 20 had a stroke and 51 a cardiovascular-related death, with 27 participants 
having multiple events. In unadjusted analyses, there was no relationship between 
MACE and PAD-medical score per unit increase (HR = 0.90, 95%CI: 0.73-1.11). In 
analyses adjusted for age, sex, IHD and stroke (Table 3), higher PAD-medical scores 
were associated with a significantly lower risk of MACE per unit increase (HR = 0.79, 
95%CI: 0.63-0.98). Of the components of the PAD-medical score only smoking 
abstinence was significantly associated with a lower risk of MACE per unit increase 
(HR = 0.61, 95%CI: 0.38-0.97).
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Table 1 Characteristics of include participants (n = 424)
Characteristic Value
Age (median years, IQR) 69 (63-76)
Gender (male, %) 311 (73.3)
Aboriginal or Torres strait islander, n (%) 19 (4.5)
Presenting problem, n (%)
Carotid artery disease 63 (14.9)
Aortic or peripheral aneurysm 121 (28.5)
Lower limb ischemia 240 (56.6)







Other anti-platelet 84 (19.8)
Statins 324 (76.4)
Metformin 251 (59.2)
Other oral hypoglycemics 154 (36.3)
Insulin 98 (23.1)
Co-morbidities, n (%)
Ischemic heart disease (IHD) 201 (47.4)
Stroke 47 (11.1)
Vitals (median, IQR)
Glycated hemoglobin (HbA1c) (%) 6.9 (6.2-7.8)
Low-density lipoprotein (LDL)-c (mmol/L) 2 (1.5-2.6)
Systolic blood pressure (mmHg) 139 (125-151)
C-reactive protein (mg/L)1 2.7 (1.0-6.0)
1C-reactive protein data is missing from 37 participants.
DISCUSSION
This study illustrates the considerable rate of clinically-important events in people that 
have PAD and diabetes, with 21% having at least one MACE during a median follow-
up of 2 years. The main finding of the study was that most people with diabetes and 
PAD do not have optimal control of modifiable risk factors for MACE. Participants 
with better implementation of medical management, as identified by higher PAD-
medical scores, had a lower of risk of MACE after adjusting for other risk factors. 
However, in sub-analyses, only smoking abstinence was found to be associated with a 
significantly reduced risk of MACE. The findings emphasize the need for methods to 
better implement medical management in people with PAD, particularly smoking 
cessation. The study also introduces a simple to use way to measure the overall 
success of control of modifiable risk factors using PAD-medical.
Previous studies show that people presenting with PAD have a higher risk of 
MACE than those frequently considered to be at the highest risk, such as those who 
have had a myocardial infarction or stroke[11]. Thus there is a need to develop 
strategies that improve the implementation of evidence-based medical therapies that 
are effective at reducing the incidence of MACE in people with PAD. Strategies to 
Golledge J et al. Medical management of peripheral artery disease
WJD https://www.wjgnet.com 888 June 15, 2021 Volume 12 Issue 6
Table 2 Association of peripheral artery disease-medical score with baseline characteristics
PAD-medical score
Risk factors
< 3.0 (n = 106) 3-3.9 (n = 145) 4.0-4.9 (n = 140) 5.0 (n = 33)
P value
Age 65 (57-73) 70 (64-77) 69 (64-77) 70 (66-76) 0.002b
Male sex 67 (63.2) 110 (75.9) 110 (78.6) 24 (72.7) 0.046a
Aboriginal or Torres Strait Islander 3 (2.8) 9 (6.2) 4 (2.9) 3 (9.1) 0.242
Presenting problem 0.043a
Carotid artery disease 12 (11.3) 19 (13.1) 27 (19.3) 5 (15.2)
Aortic or peripheral aneurysm 22 (20.8) 45 (31.0) 42 (30.0) 12 (36.4)
Lower limb ischemia 72 (67.9) 81 (55.9) 71 (50.7) 16 (48.5)
Smoking status < 0.001c
Current 55 (51.9) 41 (28.3) 5 (3.6) 0
Former 28 (26.4) 62 (42.8) 100 (71.4) 21 (63.6)
Never 22 (20.8) 42 (29.0) 35 (25.0) 12 (36.4)
IHD 38 (35.8) 64 (44.1) 75 (53.6) 24 (72.7) 0.001b
Stroke 14 (13.2) 12 (8.3) 17 (12.1) 4 (12.1) 0.606
Medications
Aspirin 34 (32.1) 96 (66.2) 118 (84.3) 30 (90.9) < 0.001c
Other anti-platelet 11 (10.4) 25 (17.2) 41 (29.3) 7 (21.2) 0.002b
Statins 58 (54.7) 115 (79.3) 121 (86.4) 30 (90.9) < 0.001c
Metformin 60 (56.6) 87 (60.0) 83 (59.3) 21 (63.6) 0.896
Other oral hypoglycemics 39 (36.8) 58 (40.0) 45 (32.1) 12 (36.4) 0.591
Insulin 26 (24.5) 35 (24.1) 33 (23.6) 4 (12.1) 0.482
HbA1c (%) 7.4 (6.8-8.7) 7.0 (6.5-7.7) 6.6 (6.0-7.6) 6.1 (5.9-6.4) < 0.001c
HDL-c (mmol/L) 1.1 (0.9-1.3) 1.1(0.9-1.3) 1.1(0.9-1.2) 0.9(0.8-1.2) 0.133
LDL-c (mmol/L) 2.60 (2.20-3.40) 2.10 (1.70-2.70) 1.60 (1.30-2.00) 1.34 (1.20-1.60) < 0.001c
SBP (mmHg) 150 (139-163) 139 (125-151) 135 (122-150) 126 (120-131) < 0.001c
C-reactive protein (mg/L) 3.0 (1.9-7.5)1 2.0 (1.0-5.0)2 3.0 (1.0-5.6)3 2.1 (0.9-5.0)4 0.082




Data are presented as number (percentage) or median (interquartile range). C-reactive protein data is missing from 91, 152, 83 and 54 participants. PAD: 
Peripheral artery disease; IHD: Ischemic heart disease; HbA1c: Hemoglobin A1c; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; SBP: 
Systolic blood pressure.
promote smoking abstinence in particular may be of highest priority given its 
association with a reduced risk of MACE in this study. It is however currently unclear 
as to what intervention strategies would be effective in achieving better imple-
mentation of these measures amongst people with PAD. Possible strategies include 
physician and patient education programs and technology-enabled reminder systems 
for medications adherence [19,38]. In order to test such interventions and their contri-
bution to achieving optimal medical management, there is a need for a simple scoring 
system to assess overall risk factor control which PAD-medical can provide.
Several models have been designed for predicting the incidence of MACE, such as 
the Framingham risk score, however these were mainly developed for use in primary 
rather than secondary prevention. The SMART-REACH model was developed for use 
in assessment of risk amongst people with established cardiovascular disease and has 
been used to model risk of MACE amongst people with PAD[39]. The SMART-
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Table 3 Association of peripheral artery disease-medical score and components with risk of major adverse cardiovascular events
Risk factor measure HR 95%CI P value
PAD-medical score 0.79 0.63 to 0.98 0.030a
LDL-C score 0.80 0.46 to 1.39 0.436
HbA1c score 0.94 0.48 to 1.83 0.853
Blood pressure score 0.59 0.30 to 1.16 0.125
Smoking abstinence 0.61 0.38 to 0.97 0.036a
Any anti-platelet 0.81 0.49 to 1.34 0.411
aP < 0.05. Adjusted for age, sex, ischemic heart disease and stroke. PAD: Peripheral artery disease; LDL: Low-density lipoprotein; HbA1c: Hemoglobin A1c.
REACH model, however, has a number of weaknesses in the assessment of the 
implementation of optimal medical management. These include the incorporation of 
risk factors not impacted by medical management, like age and sex, the lack of 
inclusion of key medical targets within the score calculation, such as HbA1c, and the 
ineligibility of some participants for the score, such as people older than 80 years. The 
PAD-medical score developed in this study aims to address these issues by strictly 
focusing on the medical management and risk factors targeted by medical manage-
ment. As demonstrated in this study the PAD-medical score provides a convenient 
way to assess how well medical management is implemented, how modifiable risk 
factors are controlled and also the risk of MACE. The PAD-medical score may 
therefore be useful in the assessment of people with PAD.
The current study has a number of limitations that should be noted. Firstly, the 
sample size included was relatively small and recruited from one state in Australia. 
Secondly, a heterogeneous group of different PAD presentations was included. 
Thirdly, there was short median duration of participant follow-up. Fourthly, sub-
analyses suggested a single risk factor (smoking abstinence) was associated with a 
lower risk of MACE. Finally, while the scoring system for PAD-medical was 
developed after considering current clinical guidelines targets[21-23], the cut-off 
values for the intermediate categories were set arbitrary. As a result of this and the 
small sample size, the findings of this study need to be validated in a more diverse 
population recruited from other localities, with a longer duration of follow-up.
CONCLUSION
This study illustrates the high incidence of clinically important events in people with 
PAD and diabetes. A simple-to-calculate score called PAD-medical is presented, which 
can be used to assess how well medical management therapy achieves control of 
modifiable risk factors. The PAD-medical score was predictive of the incidence of 
MACE during short-term follow-up.
ARTICLE HIGHLIGHTS
Research background
Peripheral artery disease is collection of chronic occlusive and aneurysmal diseases 
associated with a high incidence of major adverse cardiovascular events (MACE).
Research motivation
In this study, the control of modifiable risk factors for MACE was assessed through the 
development and testing of a new score called peripheral artery disease (PAD)-
medical.
Research objectives
The aim of this study was to assess how the PAD-medical score, which assessed the 
control of modifiable risk factors was associated with the risk of MACE in people with 
a diagnosis of both peripheral artery disease and diabetes.
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Research methods
Patients with previously diagnosed peripheral artery disease and diabetes were 
recruited from three hospitals in Queensland Australia. PAD-medical score was 
calculated as a result from zero (worst management) to five (best management) based 
on the control of modifiable risk factors and implementation of medical management. 
Cox proportional hazard analyses assessed the association of PAD-medical score (one 
unit increase) with MACE adjusted for age, sex, smoking, IHD and prior stroke.
Research results
Of 424 participants recruited less than 10% had optimal control of modifiable risk 
factors evidenced by a top PAD-medical score. A one-unit increase in PAD-medical 
was associated with a significantly lower risk of MACE after adjusting for other risk 
factors (HR = 0.79, 95%CI: 0.63-0.98). Of the five different components of PAD-
medical, only smoking abstinence was independently associated with a reduced risk of 
MACE (HR = 0.61, 95%CI: 0.38-0.97).
Research conclusions
The PAD-medical score represents an easy to use tool for the quantification of the 
control of modifiable risk factors for MACE in patients with peripheral artery disease 
and diabetes.
Research perspectives
Further research into this field requires a larger participant cohort from a more diverse 
population to investigate the wider applicability of the PAD-medical score.
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